WallStSmart
CLDI

Calidi Biotherapeutics Inc.

AMEX: CLDI · HEALTHCARE · BIOTECHNOLOGY

$0.19
-2.87% today

Updated 2026-06-05

Market cap
$3.20M
P/E ratio
P/S ratio
50.83x
EPS (TTM)
$-4.17
Dividend yield
52W range
$0 – $13
Volume
5.6M

Calidi Biotherapeutics Inc. (CLDI) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item202020212022202320242025
Total assets$1.85M$3.39M$2.60M$10.02M$14.18M$8.86M
Cash & equivalents$420000.00$2.14M$372000.00$2.05M$9.59M$5.60M
Current assets$513000.00$2.74M$786000.00$4.30M$10.23M$6.26M
Total liabilities$24.33M$26.00M$53.04M$18.25M$12.21M$5.10M
Current liabilities$8.89M$25.96M$42.99M$10.23M$9.50M$3.94M
Long-term debt$6.37M$2.06M$600000.00$600000.00
Shareholder equity$-22.48M$-22.61M$-50.44M$-8.23M$1.53M$3.76M
Retained earnings$-34.44M$-44.93M$-70.36M$-99.57M$-121.72M$-141.62M
Accounts receivable$870.00$1.36M
Inventory
Goodwill

Frequently asked questions

How much free cash flow does CLDI generate?

CLDI produced $-21.41M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CLDI's balance sheet healthy?

CLDI holds $5.60M in cash and equivalents against $600000.00 in long-term debt, on $3.76M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.